Roth Capital initiated coverage on ATAI Life Sciences with a new price target
$ATAI
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital initiated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $32.00